NMRA · Neumora Therapeutics, Inc. · Executive Compensation
$0.37
-0.02 (-5.43%)
At close · Oct 30
Return incl. dividend (before tax)
Q4 2025 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the Company expects to be able to obtain additional funding, the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$69.00M
Shares
187.90M
Volume · Oct 30
1.11M
Avg daily vol (3M)
1.45M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joshua Pinto | President | $6,743,238 |
| Paul L. Berns | Chief Executive Officer | $4,562,461 |
| Bill Aurora | Pharm.D. Chief Strategy Officer | $3,302,000 |
| Henry Gosebruch | Former President and Chief Executive Officer | $1,319,273 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul L. Berns | Executive Chairman | $8,648,393 |
| Bill Aurora | Pharm.D. Chief Strategy Officer | $5,201,926 |
| Henry Gosebruch | President and Chief Executive Officer | $4,785,930 |
| Joshua Pinto | President | $4,630,573 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Henry Gosebruch | President and Chief Executive Officer | $21,999,269 |
| Rob Lenz | Head of Research and Development | $13,582,881 |
| Paul L. Berns | Executive Chairman | $8,570,268 |
| Jason Duncan | Chief Legal Officer | $4,119,980 |
| Bill Aurora | Pharm.D. Chief Strategy Officer | $3,179,845 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Paul L. Berns | Executive Chairman and former Chief Executive Officer | $2,634,924 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Joshua Pinto | Class III director | Appointed | 2026-08-14 |
| Joshua Pinto | Chief Executive Officer | Appointed | 2026-08-14 |
| Paul L. Berns | Executive Chairperson of the Board of Directors | Appointed | 2026-08-14 |
| Kaya Pai Panandiker | Chief Commercial Officer | Resigned | 2025-02-13 |
| Carol Suh | Chief Strategy Officer | Appointed | 2025-02-13 |
| Jason Duncan | Chief Legal and Administrative Officer | Appointed | 2025-02-13 |
| Bill Aurora | Chief Operating and Development Officer | Appointed | 2025-02-13 |
| Michael Milligan | Chief Financial Officer | Appointed | 2025-02-13 |
| Henry Gosebruch | President, Chief Executive Officer | Resigned | 2025-02-13 |
| Henry Gosebruch | member of the Board | Resigned | 2025-02-13 |
| Joshua Pinto | President | Appointed | 2025-02-13 |
| Paul L. Berns | Chairman of the Board | Appointed | 2025-02-13 |
| Paul L. Berns | Chief Executive Officer | Appointed | 2025-02-13 |
Leadership
- Joshua Pinto CEO, Board Member
- Paul L. Berns CEO, Chairman, Board Member
- Michael Milligan CFO
- Bill Aurora COO
- Carol Suh COO
- Jason Duncan General Counsel
- Alaa Halawa Board Member
- David Piacquad Board Member
- Kristina Burow Board Member
- Matthew Fust Board Member
- Maykin Ho Board Member
Key facts
CIK
1885522
CUSIP
640979100
13F (30d)
22 filings
22 filers
Visit website
Investor relations